日本化学療法学会雑誌第65巻第4号
|
|
|
- あやか そや
- 5 years ago
- Views:
Transcription
1 531 総説 Key words: Staphylococcus aureus Streptococcus pneumoniae β Haemophilus influenzae Mycoplasma pneumoniae
2 532 日本化学療法学会雑誌 J U L Y I. 抗菌薬の現状を考える 1. 抗菌薬開発の動向 No. of NDA approvals ~ Year interval Penicillins Penems Carbapenems Cephems Chloramphenicols Tetracyclines Macrolides Aminoglycosides Quinolones Polipeptides Others Fig. 1. Number of antibacterial new drug application (NDA) approvals vs. year intervals in Japan.
3 533 2.多剤耐性菌の進化と新規開発抗菌薬誘導体との競り合い 3. 米国における新規抗菌薬開発の現況 Streptococcus pneumoniae
4 534 日本化学療法学会雑誌 J U L Y Table 1. The QIDP a) designation drug, provided under the U.S. GAIN b) Act Chemical compound Development company Drug discoverry company Clinical trial stage Object disease Administration Combination of Cephems and β-lactamase inhibitors 1 Ceftazidime/Avibactam Forest, AstraZeneca Avibactam: Novexel Approval ciai c), cuti d), pyelonephritis iv e) 2 Ceftolozane/tazobactam Cubist Ceftalozane: Fujisawa Approval ciai c), cuti d), pyelonephritis iv e) Tetracyclines 3 Eravacycline Tetraphase Tetraphase Clinical trial stage ciai c), cuti d) iv e), po f) 4 Omadacycline Paratek Paratek Clinical trial stage ABSSSIs g), CABP h), UTI i) iv e), po f) Macrolides 5 Solithromycin Cempra Opteimer Clinical trial stage CABP h) po f) Oxazolidinones 6 Tedizolid Cubist Toa Trius Clinical trial stage ABSSSIs g), HABP j), VABP k) iv e), po f) Quinolones 7 Delafloxacin Rib-X Wakunaga Clinical trial stage ABSSSIs g), CABP h) iv e), po f) Lipopeptides 8 Dalbavancin Durata Pfizer Approval ABSSSIs g) iv e) 9 Surotomycin Cubist Cubist Clinical trial stage CDAD l) po f) Glycopeptides 10 Oritavancin Medicines Eli Lilly Approval ABSSSIs g) iv e) Antifungal Agents 11 SCY-078 Scynexis Merck Clinical trial stage IFI m) po f) 12 Isavuconazole Astellas oharma Roche Clinical trial stage IFI m) iv e) a) QIDP, Qualified infectious disease product; b) GAIN Act, Generating antibiotic incentive law act; c) ciai, complicated intra-abdominal infections; d) cuti, complicated urinary tract infections; e) iv, intravenous; f) po, per os; g) ABSSSIs, Acute bacterial skin and skin structure Infections; h) CABP, community-acquired bacterial pneuminia; i) UTI, urinary tract infections; j) HABP, hospital-acquired bacterial pneumonia; k) VABP, ventilator-associated bacterial pneumonia; l) CDAD, Clostridium difficile-associated diarrhea; m) IFI, Invasive fungal infections Table 2. Various antibiotics immediately to be developed Antibiotic resistance threats in the United States, 2013 Microorganisms with a Threat Level of Urgent 1. Clostridium difficile 2.Carbapenem-resistant Enterobacteriaceae 3. Drug-resistant Neisseria gonorrhoeae Microorganisms with a Threat Level of Serious 4. Multidrug-resistant Acinetobacter 5.Drug-resistant Campylobacter 6. Fluconazole-resistant Candida (a fungus) 7. Extended spectrum β-lactamase producing Enterobacteriaceae (ESBLs) 8. Vancomycin-resistant Enterococcus (VRE) 9. Multidrug-resitant Pseudomonas aeruginosa 10. Drug-resistant non-typhoidal Salmonella 11. Drug-resistant Salmonella Typhi 12. Drug-resistant Shigella 13. Methicillin-resistant Staphylococcus aureus (MRSA) 14. Drug-resistant Streptococcus pneumoniae 15. Drug-resistant tubercrosis Microorganisms with a Threat Level of Concerning 16. Vancomycin-resistant Staphylococcus aureus (VRSA) 17. Erythromycin-resistant Group A Streptococcus 18. Clindamycin-resistant Group B Streptococcus The specific antibiotic resistance bacteria in Japan 19. β-lactamase-nonproducing ampicillin-resistant Haemophilus influenzae (BLNAR) 20. Macrolide-resistant Mycoplasma pneumoniae (MRMP) β Haemophilus influenzae Mycoplasma pneumoniae
5 新規抗菌薬開発にかかわる学会会員の意識レベル 5. 新規抗菌薬開発にかかわる産官学連帯の反応 S. pneumoniae M. pneumoniae
6 536 日本化学療法学会雑誌 J U L Y 第 1 部緒言と概説 I. 緒言 II. 抗菌薬療法と empiric therapy について考える 1.Empiric therapy に付き纏う宿命 Streptococcus. pyogenes S.
7 537 pneumoniae 2. 抗菌化学療法が背負う魔力 S. pneumoniae S. aureus 泂 3.Empiric therapy と耐性菌
8 538 日本化学療法学会雑誌 J U L Y III. 日本化療学会の現況を顧みて考える 1. 日本化療学会にみられる特異性 2. 新規抗菌薬の開発にみられるリスク
9 多剤耐性菌の院内感染対策に追われた官学 青字 赤字 Staphylococcus aureus β
10 540 日本化学療法学会雑誌 J U L Y Table 3. Movement toward the measure against MDR organisms and new antimicrobial drugs development in Japan (1) Year Item '82 MRSA detected from blood spreads all over the country. '85 JSIPC establishes. '86 ESBL producing bacterium is detected in Japan. '87 MHW undertakes the special research enterprise for a hospital infection. '90 MHW approved arbekacin JSCM establishes JSIPC publishes hospital infection prevention guideline '91 MHW notifies prevention of the hospital infection in health-care facilities. MHW approved vancomycin for intravenous injection '92 MHW announces the guideline of prevention of a hospital infection. 1) Health-care facilities establish the infection control committee. 2) Disinfection of fingers, sterilization of medical device, etc. '93 MHW notifies about the maintenance in health-care facilities for infection control prevention. 1) Thoroughness of the directions for an antibacterial drug 2) Education and training in connection with nosocomial infection prevention 3) Maintenance of the negative air pressure for single-patient room, or hand-washing machines 4) Hold infection-control programs for medical doctors and nurses. '94 MHW started the consultation window for infection control. MHW published Manual of the antibacterial drug therapy by JMA edit. '95 JAIS launched Board Certified Physician in Infection Control. '96 MHW installed additional reimbursement for infection prevention (5 per day). VISA was detected in Japan. VRE was detected in Europe and America. '97 MHW announces the expert meeting on the measure against drug resistant bacterium. 1) Antibacterial drug proper administration standards 2) Establishment of the system to surveillance 3) Training of medical doctor, pharmacist, nurse, and medical technologist well-acquainted with an infectious disease The National Institute of Health was reorganized by National Institute of Infectious Diseases. '98 The Infectious Diseases New Law was enacted by MHW. '99 The reorganization of IDWR was performed with enactment of a new infectious disease new law. JAID included pharmacists and medical technologists in infection-control programs. The ICD system was inaugurated by the ICD system conference. '00 MHW made additional reimbursement for infection prevention the cut to health-care facilities in which infection control committee is not working. MHW installed JANIS and expanded the indication to ICU, all the laboratories, and all the wards. MHW approved teicoplanin '01 MHW is reorganized by the Ministry of Health, Labour and Welfare (MHLW). JAID/JSC publishes Manual of antibacterial drug use together. JSIPC started the system of recognizing the education hospital for healthcare-associated infection. Note; Text in black, Announcement from MHLW,Text in blue, Events in academic societies,text in red, MDR organisms-related occurrence Glossary of abbreviations ESBLs, extended-spectrum β-latamases ICD, Infection control doctor ICU, Intensive care unit JAID, The Japanese Association for Infectious Diseases JANIS, Japan Nosocomial Infection Surveillance JMA, The Japan Medical Association JSC, Japanese Society of Chemotherapy JSCM, The Japanese Society for Clinical Microbiology JSIPC, Japanese Society for Infection Prevention and Control MDR, Multi-drugs resistant MHLW, Ministry of Health, Labour and Welfare MHW=Ministry of Heallth and Welfare MRSA, Methicillin-resistant Staphylococcus aureus VISA, Vancomycin-intermediate Staphylococcus aureus VRE, Vancomycin-resistant enterococcus 赤字
11 541 Table 4. Movement toward the measure against MDR organisms and new antimicrobial drugs development in Japan (2) Year Item '02 MHLW expanded hospital infection surveillance to operating theatre and NICU. '03 MHLW released the report of the well-informed persons meeting for infection control. MHLW added amendment to Infectious Diseases New Law. MHLW approved linezolid '04 MHLW has arranged infection-control-docter to advanced treatment hospital. MHLW reported the result of the antibacterial drug reassessment. JSCM launched the system of recognizing clinical microbiological technologist. '05 MHLW changed again the law for infection-control-and-prevention in healthcare-facilities. MHLW approved daptomycin MHLW approved tigecycline JAID/JSC publishes Guideline of antibacterial drug use together. '06 MHLW renewed additional reimbursement for infection prevention. JSCM launched the system for Infection Control Microbiological Technologist (ICMT). '07 MHLW emits warning to occurrences of hospital infection by VRE-and-MDRP in health-care facilities. MHLW updated the system of JANIS. JSC launched the system for JACP and FelLow of JACP. JSC performed the seminar for continuing education for antimicrobial stewardship. '08 MHLW notified thoroughness of nosocomial infection prevention about MDR Acinetobacter baumannii etc. The case of the hospital infection by A. baumannii was reported in Japan. MHLW approved piperacillin/tazobactam JSC launched the system for Japanese Antimicrobial Chemotherapy Pharmacist. '09 MHLW approved tebipenem JSIPC announced the guideline for the vaccine for nosocomial infection prevention. '10 MHLW announced about NDM-1-producing MDR-organism. MHLW newly set up the duty of ICT into the additional reimbursement for infection prevention. MHLW notified again hospital infection by A. baumannii in Japan. The case of the hospital infection by A.baumannii in Japan was reported again. Four academic societies (JAID, JSC, JSIPC, and JSCM) performed the joint proposal about MDR Acinetobacter infectious disease. '11 MHLW decided to publish JANIS periodically. MHLW announced the connection procedure at the time of MDR-Bacterium being detected. '12 MHLW established additional reimbursement for infection prevention regional collaboration etc. newly. JAID and JSC published the JAID/JSC guide to clinical management of infectious disease, '13 MHLW announced the connection procedure at the time of MBL-producing GNB being detected. JAID and JSC published the treatment guideline for MRSA infections. '14 MHLW announced observance of irrigation, disinfection, sterilization, etc about Infection control. Six academic societies announced the proposal jointly entitled the proposal towards development of a new antibacterial drug. JAID and JSC published the JAID/JSC GUide to Clinical Management of Infectious Disease '15 JAID ended the consultation window for infection control by the commission from MHLW. Note; Text in black, Announcement from MHLW,Text in blue, Events in academic societies,text in red, MDR organisms-related occurrence Glossary of abbreviations ICT, Infection control team GNB, Gram-negative bacilli JACP, Japanese Antimicrobial Chemotherapy Physician JAID, The Japanese Association for Infectious Diseases JANIS, Japan Nosocomial Infection Surveillance JSB, Japanese Society for Bacteriology JSC, Japanese Society of Chemotherapy JSCM, The Japanese Society for Clinical Microbiology JSIPC, Japanese Society for Infection Prevention and Control MBL, Metallo-beta-lactamase MDR, Multi-drugs resistant MDRP, Multi-drugs resistant Pseudomonas aeruginosa MHLW, Ministry of Health, Labour and Welfare MRSA, Methicillin-resistant Staphylococcus aureus NDM-1, New Delhi metallo-betalactamase NICU, Neonatal Intensive Care Unit Six academic societies, JAID, JSC, JSIPC, JSCM, JSB, and PSJ VRE, Vancomycin-resistant enterococcus IV. 感染症にかかわるガイドラインについて考える 1. 多剤耐性菌と院内感染対策 S. pneumoniae S. pneumoniae S. pneumoniae S. pneumoniae
12 542 日本化学療法学会雑誌 J U L Y 青字 2.MRSA 感染症にかかわるガイドライン
13 543 3.MRSA 感染症の原点を探る S. aureus
14 544 日本化学療法学会雑誌 J U L Y S. aureus S. aureus Streptococcus pyogenes S. aureus S. aureus S. pyogenes S. aureus S. pyogenes S. aureus S. aureus
15 545 Surgery series Internal medicine series Floor ICU 7A 7E 8F 6E 6A 5F 3F NICU 7W 9F 10E 7B 6W 6D 6F 〇 〇〇〇 〇 〇 〇 〇 〇 〇〇 〇 〇 〇〇 〇 〇〇 〇 〇 〇 〇 〇〇 〇 〇 〇 〇 〇 〇 〇 〇〇 〇 Fig. 2. Staphylococcus aureus detected from blood culture from inpatients when clinical use of third generation cephems started. Transition of MRSA from which the resistance mode to aminoglycoside differs., MSSA; 〇, GM r -MRSA;, TOB r -MRSA;, Mix r -MRSA;, Others MRSA; MSSA, methicillin-susceptible S. aureus; GM r -MRSA, gentamicin resistance type MRSA; TOB r -MRSA, tobramycin resistance type MRSA; Mix r -MRSA, gentamicin and tobramycin resistance type MRSA; Others MRSA, aminoglycoside susceptibility MRSA (Konno: Pathology for MRSA infections. IYAKU JAHNAL, Osaka/Tokyo. 1991: p. 58) ブドウ球菌の変異を知るべきである S. aureus S. aureus S. aureus S. aureus S. aureus S. aureus S. aureus meca meca
16 546 日本化学療法学会雑誌 J U L Y Table 5. The aminoglycosides resistance type, coagulase type, enterotoxin type, and phage type of MRSA which were detected from blood culture Drug rsistance type Coagulase type Enterotoxin type Phage type I: 15 III: 1 A: 22 IV: 22 I+III: 2 Nontypable: 4 GM r -MRSA A& B: 1 I: 1 (32 strains) III: 1 II: 3 B: 3 Nontypable: 2 A: 1 Nontypable: 1 TOB r -MRSA (54 strains) Mix r -MRSA (39 strains) Others MRSA (4 strains) Nontypable: 6 III: 3 B: 5 Nontypable: 2 B: 1 Nontypable: 1 III: 20 C & TSST-1: 38 I+III: 1 Nontypable: 17 II: 53 III: 8 TSST-1: 12 I+III: 1 Nontypable: 3 Nontypble: 2 III: 1 Nontypable: 1 VII: 1 A: 1 Nontypable: 1 B: 1 III: 1 III: 17 II: 33 C & TSST-1: 30 I+III: 1 Nontypable: 12 TSST-1: 1 III: 1 Nontypable: 1 Nontypable: 1 I: 1 IV: 5 A: 5 I+III: 1 Nontypable: 3 VII: 1 A: 1 III: 1 II: 3 A: 1 III: 1 Nontypable: 1 III: 1 IV: 1 C & TSST-1: 1 Nontypable: 1 GM r -MRSA, gentamicin resistance type MRSA; TOB r -MRSA, tobramycin resistance type MRSA; Mix r -MRSA, gentamicin and tobramycin resistance type MRSA; Others MRSA, aminoglycoside susceptibility MRSA (Konno: Pathology for MRSA infections. IYAKU JAHNAL, Osaka/Tokyo. 1991: p. 64)
17 547 mec S. aureus 5.MRSA 感染症防止に何が必要か S. pneumoniae S. aureus S. aureus S. aureus S. aureus meca 文献
18 548 日本化学療法学会雑誌 J U L Y Haemophilus influenzae Mycoplasma pneumoniae
19 549 β β Klebsiella pneumoniae β Staphylococcus aureus Staphylococcus aureus Staphylococcus aureus Staphylococcus aureus S. aureus Staphylococcus aureus Staphylococcus albus Staphylococcus aureus β β Staphylococcus aureus meca Staphylococcus aureus
20 550 日本化学療法学会雑誌 J U L Y Staphylococcus aureus mec Staphylococcus aureus Staphylococcus aureus
21 551
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 53 53 Tebipenem pivoxil 1 1, 3 2 2 1 1 Meiji Seika 2 Meiji Seika G 3 Meiji Seika 2015 12 15 Tebipenem pivoxil 10% 2010 4 2013 3 3,547 3,540 3,540 3,331
CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
第26回日本環境感染学会総会プログラム・抄録集 Part1
26 26 26 26 26 2009 Klebsiella pneumoniae producing carbapenemasekpcmulti-drug resistant Acinetobacter baumannii MDRAbNew Delhi Metallo--Lactamase-1NDM-1 WHO CDC John BoyceDidier Pittet William RutalaCLA-BSIMark
THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
日本化学療法学会雑誌第58巻第4号
Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p
600mg 600mg CTD 2 2.5 2.5 Page 3 2.5...7 2.5.1...7 2.5.2...27 2.5.3...28 2.5.4...42 2.5.5...55 2.5.6...79 2.5.7...97 2.5 Page 5 73 67 31 48 48A 102 104 105 106 ALP ALT(GPT) AST(GOT) AUC AUEC BID BUN
CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 1 1 2013 69 11,762 2015 11 16 1994 2013 69 19 11,762 FQ 33 Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr NTT NTT
Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 121 23 7 7 IDSA 122 24 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr. 2012 7 2005 3 10 7 2011 6 2 NTT NTT 2011 6 Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS
Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus
2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1
2108 CHEMOTHERAPY SEPT. 1977 Table 1 Antimicrobial spectrum Fig. 1 VOL. 25 NO. 7 CHEM 014 HERAPY 2109 Table 2 Susceptibility distribution of Staphylococcus aureus to aminoglycosides (54 strains) Table
b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
日本化学療法学会雑誌第65巻第4号
Mycoplasma pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae Key words Mycoplasma pneumoniae Mycoplasma pneumoniae M. pneumoniae I M. pneumoniae M. pneumoniae M. pneumoniae
Fig. 1 Chemical structure of KW-1070
Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.
Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo
Kekkaku Vol. 79, No. 1: 17-24, 2004 17 (Received 21 Aug. 2003/Accepted 18 Nov. 2003) Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
DIC vegetation 1 nonbacterial thrombogenic e
2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus
Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis
Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM)
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium
VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum
VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae methicillin-resistant Staphylococcus
日本化学療法学会雑誌第59巻第5号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
CHEMOTHERAPY OCT. 1994 Tazobactam Piperacillin Fig. I. Chemical structures of tazobactam and piperacillin. Table 1. Media used for preculture and MIC determination BHIB: Brain heart infusion broth (Difco),
13●53頁●６－７▲院内感染対策▲.ppt
No.610 1 No.121 2 No.128 Nosocomial infection, Hospital-acquired infection CDC nosocomial infection, hospital-acquired infection nosocomial nosokomeion hospital nosocomial infection nosocomial pneumonia
Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書（案）
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
４月号 学会特集号 １２２２４７／１６）一般演題目次
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 48 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 49 60 61 62 63 64 65 66 67 68
1) i) Barber, M. et al.: Brit. Med J, 2, 565, 19'49. ii) Barber, M.F.G. J. Hayhoe and J. E. M. Whithead: Lancet, 1120 `1125, 1949.-2) Bergey: Bergey's Manual of Determinative Bacteriology 7 th Ed: (1958).-3)
Oct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz
Oct. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 5 327 27 2013 2014 2016 7 5 2013 2014 Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, tazobactam/piperacillin TAZ/PIPC, ceftazidime CAZ, cefepime
HPM_442_F_TgCHG_1128
3M TM Chlorhexidine Gluconate IV Securement Dressings Tegaderm TM CHG Support CRBSI Prevention TegadermTM CHG Dressing 2w/w% 60% N. Safdar, Intensive Care Med 2004 30 62-7 Guideline Centers for Disease
(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia
Key words: Blood culture, Trend of bacterial isolation, Increasing of staphylococcus, Use of new cephems (ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor
indd
24 61 1 2011 調査 研究 1 2 1 1 2 4 1 3 4 1 2 1 2 1 2 1 2 2 1 1 2 3 4 2010 11 11 2011 1 7 Infection Control in an Endoscopy Room Multi - society Guideline and Current Status at Fukushima Medical University
Key words: MRSA, Blood culture, TSST-1, Phage type, theory of quantification Table 1 Antibiotic resistant patterns of S. aureus isolated from blood cultures during 1984.1-1986.4 MRSA: methicillin-resistant
Fig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
VOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin
VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin 1380 CHEMOTHERAPY MAR. 1975 Table 2 Susceptibility of isolated Pseudomonas aeruginosa to various antibiotics
Fig. 1 The sketch of the neonatal intensive care unit in Tokyo Women's Medical College Hospital. (1979)
Key words: neonatal intensive care unit, bacterial contamination, Pseudomonas, Stophylococcus Fig. 1 The sketch of the neonatal intensive care unit in Tokyo Women's Medical College Hospital. (1979) Table
untitled
Quantitative Risk Assessment on the Public Health Impact of Pathogenic Vibrio parahaemolyticus in Raw Oyster 1 15 5 23 48 2 21 1 16 1 16 1 11 3 1 3 4 23 1 2 16 12 16 5 6 Hazard IdentificationExposure
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,
CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str
cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus
VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia
ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
VOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover
VOL.26 S-2 CHEMOTHERAPY Gentamicin (GM), Dibekacin (DKB), Tobramycin Fig. 1 Protein concentration and protein binding rate Table 2 Protein binding rate of PC-904 in serum of healthy adults, and patients
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S. Table 1. Clinical summary of acute uncomplicated cystitis patients treated with 7432-S UTI : Criteria by the
Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
Table 1. Antimicrobial drugs using for MIC
Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive
Table1MIC of BAY o 9867 against standard strains
Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative
CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);
VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical
日本化学療法学会雑誌第60巻第4号
Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae Key words β Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae μ μ S. pneumoniae H. influenzae S. pneumoniae
CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk
VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,
CHEMOTHERAPY MAY. 1988
CHEMOTHERAPY MAY. 1988 CHEMOTHERAPY Fig. 1 Chemical structure CHEMOTHERAPY MAY. 1988 VOL.36 5-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY
Table 1 Laboratory data on admission * : Bacterial examinations were done on February 2, 1995 Fig. 1 Clinical course
Key words : psoas abscess, diabetes mellitus Table 1 Laboratory data on admission * : Bacterial examinations were done on February 2, 1995 Fig. 1 Clinical course 高齢 者 に発 症 した腸 腰 筋 膿 瘍 の1例 Fig. 2 Pelvic
公開情報 2016 年 1 月 ~12 月年報 院内感染対策サーベイランス集中治療室部門 3. 感染症発生率感染症発生件数の合計は 981 件であった 人工呼吸器関連肺炎の発生率が 1.5 件 / 1,000 患者 日 (499 件 ) と最も多く 次いでカテーテル関連血流感染症が 0.8 件 /
公開情報 2016 年 1 月 ~12 月年報 院内感染対策サーベイランス集中治療室部門 集中治療室(ICU) 部門におけるサーベイランスの概要と目的 本サーベイランスの目的は 集中治療室 (Intensive Care Unit : ICU) における人工呼吸器関連肺炎 尿路感染症 カテーテル関連血流感染症の発生状況 * を明らかにすることである 集計対象医療機関の各感染症発生率を 1,000 患者
Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic
日本化学療法学会雑誌第55巻第S-1号
µ µ Key words Streptococcus pneu- moniae S. pneumoniae µ µ I γ H H C HN F F O N O CO H H C SO H H O Fig.. ChemicalstructureofGRNX. γ γ II Haemophilus influenzae Pseudomonas aeruginosa Streptococcus intermedius
CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc
APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus
988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination
Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination Fig. 1. The following three kinds of overnight broth cultures of 10 strains of Kl. pneumoniae were inoculated on the agar
) ,
Vol. 2, 1 17, 2013 1986 A study about the development of the basic policy in the field of reform of China s sports system 1986 HaoWen Wu Abstract: This study focuses on the development of the basic policy
CHEMOTHERAPY JUNE 1986
VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml
03-b-„FŒ{›xŒ¾-4.02
518( 30 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 1. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 519( 31 ) 9 5 2003 8 2004 7 14 565 701 258 (36.8%) 443 (63.2%) Staphylococcus aureus
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
17 (VAP: Ventilator-associated pneumonia) ICU 6 52 [1] VAP 3 4 Streptococcus pneumonia Haemophilus Influenzae Staphylococcus aureus Pseudomonas
![17 (VAP: Ventilator-associated pneumonia) ICU 6 52 [1] VAP 3 4 Streptococcus pneumonia Haemophilus Influenzae Staphylococcus aureus Pseudomonas](/thumbs/94/118614761.jpg "17 (VAP: Ventilator-associated pneumonia) ICU 6 52 [1] VAP 3 4 Streptococcus pneumonia Haemophilus Influenzae Staphylococcus aureus Pseudomonas")
17 (VAP: Ventilator-associated pneumonia) ICU 6 52 [1] 1 3 30 VAP 3 4 Streptococcus pneumonia Haemophilus Influenzae Staphylococcus aureus Pseudomonas aeruginosa MRSA Acinetobacter species Enterobacter
123 昭 和49年4月20日 写 真4 写 真1 写 真2 指摘 が最 初 の もの と思 わ れ る. イ菌 感 染症 は イ菌 が 抗 生 剤 に 感 受 性 を 有 す る限 り,そ の化 学 療 法 効 果 が 期 待 出 来 るが,化 学 療 法 を 中 止す る と再 度 出現 す る症 例 が 多 い こ とに気 付 き,エ コ ロジ カル に検 討 した と ころ,三 病型 に分
日本化学療法学会雑誌第57巻第6号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae S. pneumoniae β β H. influenzae S. pneumoniae H. influenzae M. catarrhalis Key words Otalgia Fever Item Crying,Iritation,
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. aeruginosa 30, P. maltophilia pyogenes 32, Escherichia
CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
Table 1.Distribution and number of cases with acute upper respiratory tract infections classified according to antimicrobial agents administered Table 2. Distribution of cases which were enrolled to set
Feb THE JAPANESE JOURNAL OF ANTIBIOTICS ,4 2,4 2,4 2,3,4 2,3,4 2,3, ,3, Garenoxacin GRNX Levofloxacin LV
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 27 27 1,4 2,4 2,4 2,3,4 2,3,4 2,3,4 2 1 2,3,4 1 2 3 4 2015 10 21 9 Garenoxacin GRNX Levofloxacin LVFX Sitafloxacin STFX Moxifloxacin MFLX Pharmacokinetics-Pharmacodynamics